Portfolio Analysis in Geneva.

A patent portfolio analysis Geneva innovators can rely on begins where the world’s intellectual-property systems are actually administered, because Geneva is the global capital of IP. The World Intellectual Property Organization (WIPO) is headquartered here, and it runs the Patent Cooperation Treaty, the Madrid trademark system and the Hague designs system from the shore of Lake Geneva.

Yet the rights themselves are Swiss, and Switzerland sits deliberately apart from the European mainstream. Patents are granted by the Swiss Federal Institute of Intellectual Property in Bern, litigated before the Federal Patent Court in St. Gallen, and — from 1 January 2027 — examined under a reformed Patents Act. Switzerland is not in the EU or the Unified Patent Court, so a Geneva portfolio has to be scoped as its own strategic territory. PerspireIP builds the analysis that connects a Geneva company’s inventions to that unusual, treaty-rich landscape.

Why a patent portfolio analysis Geneva strategy runs through WIPO’s front door

No other city in the world puts the machinery of international IP quite so close to the companies that use it. The World Intellectual Property Organization (WIPO) has its headquarters in Geneva, and from there it administers the treaties that turn a single invention into worldwide protection — the Patent Cooperation Treaty (PCT) for patents, the Madrid System for trademarks and the Hague System for industrial designs. For a Geneva-based patentee, the body that governs how international filings work is a local institution, not a distant abstraction.

That proximity shapes strategy. A great many Geneva companies file first through the PCT, using the international phase to keep options open across dozens of markets before committing to national validation costs. Portfolio analysis in this city therefore has to think in PCT terms from the outset: which international applications are alive, where their 30- and 31-month national-phase deadlines fall, and which markets each family should actually enter. The same logic extends to Madrid trademarks and Hague designs, the natural companions to a patent estate in a luxury or consumer-facing business.

• WIPO, Geneva — administers the PCT (158 contracting states), the Madrid trademark system and the Hague designs system
• WIPO Arbitration and Mediation Center, Geneva — resolves cross-border IP and technology disputes, including domain-name and licensing matters
• World Trade Organization (WTO), Geneva — home of the TRIPS Agreement that sets the global floor for IP protection
• Swiss Federal Institute of Intellectual Property (IPI/IGE), Bern — grants and administers national Swiss patents, SPCs and trademarks

The practical upshot is that a Geneva portfolio should be read as an international instrument that happens to sit on Swiss soil. We map each family from its priority filing and PCT application outward, so counsel can see the whole international structure — not just the Swiss endpoint — and decide where the budget genuinely earns its keep.

Where a Geneva patent is granted, litigated and reformed

Although Geneva hosts WIPO, the Swiss rights themselves are granted and enforced through a distinctly national system. The Swiss Federal Institute of Intellectual Property (IPI, or IGE in German), based in Bern, is the office that grants Swiss patents. Historically it examined applications only for formal requirements and excluded subject matter — not for novelty or inventive step — which made the Swiss patent unusually easy to obtain but weaker to assert until tested in court.

Disputes do not stay in Geneva. Switzerland concentrates all patent litigation in a single specialised forum: the Federal Patent Court (Bundespatentgericht / Tribunal fédéral des brevets) in St. Gallen, which holds exclusive first-instance jurisdiction over patent infringement and validity for the whole country. Its panels mix legally trained and technically qualified judges, and appeals run to the Swiss Federal Supreme Court in Lausanne. A Geneva watchmaker, biotech or trading house asserting or defending a patent litigates in St. Gallen, not in any Geneva cantonal court.

The other decisive fact is that Switzerland stands outside the European Union and outside the Unified Patent Court. A unitary patent has no effect here, and the UPC has no jurisdiction over Swiss rights. The Swiss designation of a European patent is an independent national right, enforced only in St. Gallen. For a Geneva company with a pan-European product, that means the Swiss part of the portfolio has to be valued, defended and litigated on its own track, separate from any EU-wide campaign — a distinction any credible portfolio analysis has to draw sharply.

The 2027 Swiss examination reform and what it changes for your estate

The biggest shift in decades is arriving on 1 January 2027, when a partially revised Swiss Patents Act comes into force. For the first time the IPI will offer a full substantive examination — a search of the state of the art and an assessment of novelty and inventive step — bringing the national Swiss patent into line with international standards. Applicants will be able to choose: keep the traditional partially examined patent, or request a fully examined one.

The fee structure follows that choice. Under the reform the application fee of CHF 200 will cover 15 claims instead of ten, a search fee of CHF 500 applies, and full examination for novelty and inventive step carries an additional CHF 300. Most applications already pending when the law takes effect, and for which the examination fee has not yet been paid, will fall under the new regime automatically. That transition has real consequences for anyone holding or filing Swiss national rights.

A forward-looking patent portfolio analysis Geneva companies commission now should model both worlds. A fully examined Swiss patent is far more robust to assert before the Federal Patent Court and far more attractive to a licensee or acquirer; a partially examined one remains cheap and fast but carries validity risk that only surfaces in litigation. We flag which pending Swiss cases would benefit from full examination, and which are better routed through the European patent (which is already substantively examined by the EPO) and validated in Switzerland instead.

Geneva’s inventive base: watches, luxury, flavours, pharma and deep tech

Geneva’s patents look like Geneva’s economy, and that economy is unusually distinctive. The region is the heart of Swiss haute horlogerie and luxury: Rolex is headquartered in the Acacias district, Patek Philippe and Vacheron Constantin keep their watchmaking in the city, and the Richemont group manages a stable of luxury maisons from greater Geneva. These businesses live and die by a blend of technical patents (escapements, movements, materials), design rights and trademarks — the classic case for a coordinated patent, Hague-design and Madrid-trademark portfolio.

• Watchmaking and luxury — movements, complications, materials and case designs, protected by patents, Hague designs and Madrid trademarks (Rolex, Patek Philippe, Vacheron Constantin, Richemont)
• Flavours, fragrances and specialty chemistry — dsm-firmenich, headquartered in the Geneva area, and a deep bench of formulation and process patents
• Pharma, biotech and Health Valley — life-science innovators around Lake Geneva whose value rides on patents and supplementary protection certificates
• Deep tech and detector science — CERN and the University of Geneva generate physics, sensor and computing inventions with heavy licensing potential
• Commodity trading and fintech — platform, data and process inventions from Geneva’s finance and trading cluster

Each of these sectors stresses a portfolio differently. A luxury house needs its patents, designs and marks read as one interlocking estate; a flavours or pharma company needs its patent term extended by supplementary protection certificates; a CERN spin-out needs a licensing-ready map of who owns what. A generic city-swapped template cannot see those differences — a genuine Geneva analysis has to.

PCT-centric international filing strategy from Geneva’s doorstep

Because WIPO runs the PCT from Geneva, the international application is the natural spine of a Geneva patent strategy. The PCT lets a company file one international application, secure an international search report and written opinion, and defer the expensive national-phase decisions for up to 30 or 31 months from priority. For a fast-moving watch, flavour or deep-tech business, that breathing room is the whole point — but only if the family is actively managed rather than left to drift toward its deadlines.

This is where a patent portfolio analysis Geneva teams commission earns its return. We inventory every live PCT family, plot each national-phase deadline, and pressure-test the market list against where the company actually sells, manufactures and faces competitors. A Geneva luxury brand may need broad coverage across the EU, US, China, Japan and the Gulf; a niche instrumentation maker may need only three or four markets. Entering too many wastes budget on maintenance fees; entering too few leaves the invention exposed exactly where it is copied.

The patent map also has to sit alongside the trademark and design estate. WIPO’s Madrid System extends a trademark across scores of countries from a single filing, and its Hague System does the same for industrial designs — both indispensable to a luxury or consumer business. We show how the three registries interlock, so a Geneva company sees one coherent international estate instead of three disconnected filing programmes.

CH+LI validation, SPCs and the true cost of a European portfolio

For most Geneva companies, the European patent is the workhorse and the Swiss right is one designation within it. Here Switzerland offers a genuine efficiency: under a bilateral treaty, Switzerland and Liechtenstein form a single unified patent territory. A European patent is validated jointly for both through one designation under Article 149 EPC, it takes effect automatically on grant, and there is no post-grant translation requirement. One decision, one fee, two countries covered — a rare simplification in an otherwise fragmented European landscape.

Pharma and life-science portfolios add another layer. The IPI grants supplementary protection certificates (SPCs) that extend patent protection for an authorised medicinal product by up to five years beyond the 20-year term, provided a Swiss marketing authorisation exists and the application is filed within six months of that authorisation (or of patent grant, if later). A further six-month paediatric extension has been available since January 2019. For a Geneva biotech or a Health Valley pharma company, these certificates are frequently the single most valuable rights in the estate.

Cost analysis pulls all of this together. We tally renewal fees across each validated country, model the Swiss and EU tracks separately because they diverge outside the UPC, factor in SPC term and paediatric extensions where they apply, and identify families that are quietly draining maintenance budgets without protecting a live product. The output is a clear picture of what the European portfolio actually costs to keep — and where it can be pruned without losing anything that matters.

How PerspireIP builds a patent portfolio analysis Geneva teams act on

We work as the analytical arm behind Geneva’s IP counsel and in-house teams, turning a scattered collection of filings into a portfolio a board can actually reason about. That means a family-by-family inventory of patents, PCT applications, European validations, Swiss national rights, SPCs, Madrid trademarks and Hague designs — each mapped to its status, its deadlines, its markets and the product or product line it protects.

• Full portfolio inventory and mapping — patents, PCT families, EP/CH+LI validations, SPCs, and companion Madrid and Hague rights
• PCT national-phase planning — deadline tracking and market-by-market entry recommendations for each live family
• 2027 reform readiness — guidance on which Swiss national cases warrant full substantive examination versus the EPO route
• Renewal and cost analysis — country-by-country fee modelling, Swiss-versus-EU tracks, and pruning of dead-weight families
• Landscape and white-space mapping — competitor filings, freedom-to-operate context and gaps worth filing into
• Licensing and transaction support — clean, defensible portfolio maps for CERN-style spin-outs, M&A and in/out-licensing

Everything is scoped to Geneva’s realities: the WIPO-centred international filing culture, the industries the city actually produces — watches and luxury, flavours and fragrances, pharma and deep tech — the Federal Patent Court in St. Gallen that would hear any dispute, and Switzerland’s position outside the UPC. A patent portfolio analysis Geneva companies can act on is never a template with the city name swapped in; it is a document that reflects this specific, treaty-rich environment.

Whether you are a luxury maison coordinating patents, designs and marks, a Health Valley biotech protecting an SPC-extended drug, a CERN spin-out packaging technology for licensing, or a trading house rationalising a sprawling estate, we scale to fit. Send us your patent families or a filing list and your key markets, and we will scope a patent portfolio analysis Geneva project within one business day, working confidentially alongside your Swiss and international counsel.

IP Landscape & Resources in Geneva

Key intellectual-property authorities and venues relevant to Geneva:

• Swiss Federal Institute of Intellectual Property (IPI/IGE) — the Swiss patent and trademark office in Bern that grants national patents, SPCs and trademarks and runs the 2027 examination reform
• World Intellectual Property Organization (WIPO) — the UN agency headquartered in Geneva that administers the PCT, Madrid and Hague international systems
• Swiss Federal Patent Court (Bundespatentgericht) — the court in St. Gallen with exclusive national jurisdiction over Swiss patent infringement and validity
• European Patent Office (EPO) — grants the European patents that are validated jointly for Switzerland and Liechtenstein

Request a Patent Portfolio Analysis in Geneva

Explore related PerspireIP services: Patent Portfolio Analysis · Patent Invalidation · Prior Art Search · Patent Landscape Analysis.

Frequently Asked Questions